Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0206708
Disease: Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia
0.030 GeneticVariation disease BEFREE : The study included 188 women who consecutively attended a colposcopy clinic because of PAP smears suggesting cervical intraepithelial neoplasia (CIN), and 40 women with normal vaginal cytology. 21558960 2011
CUI: C0206708
Disease: Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia
0.030 Biomarker disease BEFREE Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. 16023184 2005
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 AlteredExpression group BEFREE Three genes encoding related proteins, PAP, reg Ialpha and reg Ibeta, were over-expressed in cancer. 10328217 1999
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease
0.020 Biomarker disease BEFREE Risk-adjusted analyses demonstrated higher PP (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.20-1.45; P < .001), PAP (aHR, 1.32; 95% CI, 1.19-1.45; P < .001), SP (aHR, 1.47; 95% CI, 1.31-1.65; P < .001), limb salvage (aHR, 1.48; 95% CI, 1.30-1.67; P < .001), and patient survival (aHR, 2.42; 95% CI, 2.17-2.71; P < .001) for RT compared with HD patients. 30583904 2019
CUI: C0020179
Disease: Huntington Disease
Huntington Disease
0.020 Biomarker disease BEFREE Risk-adjusted analyses demonstrated higher PP (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.20-1.45; P < .001), PAP (aHR, 1.32; 95% CI, 1.19-1.45; P < .001), SP (aHR, 1.47; 95% CI, 1.31-1.65; P < .001), limb salvage (aHR, 1.48; 95% CI, 1.30-1.67; P < .001), and patient survival (aHR, 2.42; 95% CI, 2.17-2.71; P < .001) for RT compared with HD patients. 30583904 2019
CUI: C0037315
Disease: Sleep Apnea Syndromes
Sleep Apnea Syndromes
0.020 Biomarker disease BEFREE Approaches to diagnosing and treating sleep apnea that emphasized early application of auto-PAP had lower per-patient costs. 29066589 2018
CUI: C0030305
Disease: Pancreatitis
Pancreatitis
0.020 AlteredExpression disease BEFREE The aim of this study was to determine the impact and clinical relevance of the peritumoral microenvironment, through pancreatitis-associated protein (PAP/REG3A) expression, on PNI in pancreatic cancer. 28656348 2017
CUI: C0037315
Disease: Sleep Apnea Syndromes
Sleep Apnea Syndromes
0.020 Biomarker disease BEFREE Treating sleep apnea in Parkinson's disease with C-PAP: feasibility concerns and effects on cognition and alertness. 28449889 2017
CUI: C0038436
Disease: Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder
0.020 Biomarker disease BEFREE Research is warranted on advanced PAP modes in managing CPAP failure in PTSD patients with comorbid OSA. 29200833 2017
CUI: C0038436
Disease: Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder
0.020 Biomarker disease BEFREE Treatment of OSA with PAP therapy is associated with improvement in PTSD symptoms, although the mechanism is unclear. 27707436 2017
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease
0.020 AlteredExpression disease BEFREE We conclude that the Hp 2 type is associated with elevated s-PAP levels and low plasma nitrite levels in HD patients specifically in the DM state. 26171400 2015
CUI: C0020179
Disease: Huntington Disease
Huntington Disease
0.020 AlteredExpression disease BEFREE We conclude that the Hp 2 type is associated with elevated s-PAP levels and low plasma nitrite levels in HD patients specifically in the DM state. 26171400 2015
CUI: C0030305
Disease: Pancreatitis
Pancreatitis
0.020 Biomarker disease BEFREE This transcript has been mainly referred to in the literature as pancreatitis-associated protein (PAP/RegIIIα). 26187439 2015
CUI: C0003578
Disease: Apnea
Apnea
0.010 GeneticVariation phenotype BEFREE Knowing about risk factors for residual apnoeic-hypopnoeic events may assist in the timely provision of personalized care including the type of PAP therapy, attention to co-morbidities and choice of interface. 31336407 2020
CUI: C0000768
Disease: Congenital Abnormality
Congenital Abnormality
0.010 Biomarker group BEFREE Herein we describe the epidemiological characteristics of I-PAP in 697 newborns, 383 males and 314 females identified in 1,178,993 examined live births from a multicenter case-control hospital-based population study, the Mexican program of Registry and Epidemiological Surveillance of Congenital Malformations (RYVEMCE). 31091006 2019
CUI: C0007868
Disease: Cervical dysplasia
Cervical dysplasia
0.010 GeneticVariation disease BEFREE Cases were categorized as cervical dysplasia only (S2) or cervical dysplasia with conization (S1) and compared to healthy controls with a normal PAP smear. 30374649 2019
CUI: C0009319
Disease: Colitis
Colitis
0.010 Biomarker disease BEFREE PAP protein plays a protective effect presenting anti-inflammatory properties able to reduce the severity of colitis, preserving gut barrier and epithelial inflammation. 31325218 2019
CUI: C0021364
Disease: Male infertility
Male infertility
0.010 AlteredExpression phenotype BEFREE The study indicated that miR-125b-2 had a positive influence on the reproductive performance of animals by regulating the expression of the PAP gene, and could be a potential drugs and diagnostic target for male infertility. 30609807 2019
CUI: C0024117
Disease: Chronic Obstructive Airway Disease
Chronic Obstructive Airway Disease
0.010 Biomarker disease BEFREE Our results suggest that patients' symptoms in symptomatic COPD groups B and D might be related to increased PAP and concomitant cardiovascular comorbidities. 31037993 2019
CUI: C0033975
Disease: Psychotic Disorders
Psychotic Disorders
0.010 Biomarker group BEFREE Many studies show psychoses after some antiepileptic drug (AED) administrations (post-AED administration psychoses [PAP]). 31252268 2019
CUI: C0242670
Disease: Persistent Vegetative State
Persistent Vegetative State
0.010 Biomarker disease BEFREE Given the importance of PH in this disease, clinical studies of PVS treatments should include measures of PAP and RV function as important variables of interest. 29708022 2019
CUI: C0002736
Disease: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
0.010 Biomarker disease BEFREE Survival duration (time elapsed from baseline onset until death) is compared on the basis of Bi-PAP initiation threshold (FVC %predict); daily Bi-PAP usage protocol (hours/day); daily cough assist usage (users or non-users); ALS onset type; ALSFRS-R score; and time elapsed from baseline onset until Bi-PAP initiation, using Kruskal-Wallis one-way analysis of variance and Kaplan Meier. 30050497 2018
CUI: C0003811
Disease: Cardiac Arrhythmia
Cardiac Arrhythmia
0.010 Biomarker phenotype BEFREE This case provides support in favor of a bidirectional relationship between SDB and AF and suggests that data available from PAP machines may be useful in serial assessment of SDB status relative to heart rhythm. 30373693 2018
CUI: C0004238
Disease: Atrial Fibrillation
Atrial Fibrillation
0.010 Biomarker disease BEFREE This case provides support in favor of a bidirectional relationship between SDB and AF and suggests that data available from PAP machines may be useful in serial assessment of SDB status relative to heart rhythm. 30373693 2018
CUI: C0010200
Disease: Coughing
Coughing
0.010 Biomarker phenotype BEFREE Survival duration (time elapsed from baseline onset until death) is compared on the basis of Bi-PAP initiation threshold (FVC %predict); daily Bi-PAP usage protocol (hours/day); daily cough assist usage (users or non-users); ALS onset type; ALSFRS-R score; and time elapsed from baseline onset until Bi-PAP initiation, using Kruskal-Wallis one-way analysis of variance and Kaplan Meier. 30050497 2018